An observational study in Cardiovascular Diseases, Coronary Artery Disease and Heart Failure, sponsored by Inha University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Inha University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This multicenter retrospective study aims to develop, validate, and clinically apply an artificial intelligence (AI)-powered electrocardiography (ECG) algorithm for the diagnosis and prognostic prediction of cardiovascular diseases, including coronary artery disease and heart failure. By utilizing encrypted raw 12-lead ECG text data and deep neural network models, the study evaluates the effectiveness of AI-enhanced ECG in detecting cardiac abnormalities and predicting clinical outcomes.
Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality. Standard 12-lead ECGs are widely accessible tools for cardiovascular screening and diagnosis; however, traditional visual interpretations have limitations. Recent advancements in deep learning offer unprecedented performance in extracting hidden patterns from ECG signals.
This study is a retrospective, multicenter investigation conducted across multiple tertiary medical centers in South Korea. The primary objectives are:
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Inha University Hospital is the lead sponsor of 37 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients visiting the participating tertiary hospitals with extractable electrocardiogram records and diagnosed with cardiovascular diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Patients deemed inappropriate as study subjects by the investigator's judgment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients aged 18 years or older diagnosed with cardiovascular diseases, including coronary artery disease and heart failure, who have extractable text-format (XML) 12-lead electrocardiogram records.
Other: Retrospective ECG Data Analysis
Analysis of de-identified 12-lead electrocardiogram raw data using deep learning models for cardiovascular disease diagnosis and prognosis.
Diagnostic Performance (AUC-ROC) of AI-ECG Models
To evaluate the area under the receiver operating characteristic curve (AUC-ROC) of the deep neural network-based 12-lead ECG model for diagnosing cardiovascular diseases compared to reference clinical standards.
Time frame: Baseline
Sensitivity and Specificity of AI-ECG Models
To evaluate the association between AI-ECG risk scores and long-term clinical outcomes, including all-cause mortality and heart failure-related hospitalizations.
Time frame: Baseline
Plan to share: No — Data are not available due to institutional policy and patient privacy regulations regarding retrospective clinical records.
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.
Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 60 months is below that.
Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inha University Hospital